IL6 and fibrosarcoma: The crucial dependence of the CHX207 model on IL‐6 renders it suitable for studying the efficacy of STAT3 inhibitors (e.g. sorafenib), IL‐6‐, or IL‐6 receptor blocking antibodies (e.g. tocilizumab) to prevent fibrosarcoma‐induced cachexia.